XILIO THERAPEUTICS INC (XLO) Fundamental Analysis & Valuation

NASDAQ:XLO • US98422T1007

Current stock price

8.51 USD
+0.03 (+0.35%)
Last:

This XLO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. XLO Profitability Analysis

1.1 Basic Checks

  • XLO had negative earnings in the past year.
  • XLO had a negative operating cash flow in the past year.
  • XLO had negative earnings in each of the past 5 years.
  • In the past 5 years XLO always reported negative operating cash flow.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • XLO has a Return On Assets (-43.75%) which is in line with its industry peers.
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

  • XLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XLO Health Analysis

2.1 Basic Checks

  • XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -2.30, we must say that XLO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.30, XLO perfoms like the industry average, outperforming 49.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.3
ROIC/WACCN/A
WACC9.2%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • XLO has a Current Ratio of 2.20. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.20, XLO is not doing good in the industry: 74.08% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.20 indicates that XLO has no problem at all paying its short term obligations.
  • XLO's Quick ratio of 2.20 is on the low side compared to the rest of the industry. XLO is outperformed by 72.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 2.2
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. XLO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.76% over the past year.
EPS 1Y (TTM)76.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%693.85%

3.2 Future

  • XLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.85% yearly.
  • The Revenue is expected to decrease by -43.89% on average over the next years. This is quite bad
EPS Next Y36.91%
EPS Next 2Y-29.71%
EPS Next 3Y23.42%
EPS Next 5Y17.85%
Revenue Next Year79.08%
Revenue Next 2Y-46.55%
Revenue Next 3Y-56.47%
Revenue Next 5Y-43.89%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. XLO Valuation Analysis

4.1 Price/Earnings Ratio

  • XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as XLO's earnings are expected to grow with 23.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.71%
EPS Next 3Y23.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XLO Dividend Analysis

5.1 Amount

  • No dividends for XLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XLO Fundamentals: All Metrics, Ratios and Statistics

XILIO THERAPEUTICS INC

NASDAQ:XLO (4/2/2026, 8:02:03 PM)

8.51

+0.03 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)N/A
Inst Owners33.67%
Inst Owner Change86.85%
Ins Owners0.68%
Ins Owner Change0.56%
Market Cap574.77M
Revenue(TTM)N/A
Net Income(TTM)-58.49M
Analysts84
Price Target28.56 (235.61%)
Short Float %N/A
Short Ratio5.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.91%
Min EPS beat(2)-98.02%
Max EPS beat(2)80.2%
EPS beat(4)2
Avg EPS beat(4)-74.2%
Min EPS beat(4)-287.6%
Max EPS beat(4)80.2%
EPS beat(8)4
Avg EPS beat(8)-88.69%
EPS beat(12)7
Avg EPS beat(12)-55.03%
EPS beat(16)10
Avg EPS beat(16)-38.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.6%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)1.3%
Revenue beat(4)1
Avg Revenue beat(4)-20.89%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)1.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1300%
PT rev (3m)1300%
EPS NQ rev (1m)-1300%
EPS NQ rev (3m)-1300%
EPS NY rev (1m)-1300%
EPS NY rev (3m)-1300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.03
EYN/A
EPS(NY)-2.55
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.47
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.93%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 2.2
Altman-Z -2.3
F-Score6
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%128.93%
EPS Next Y36.91%
EPS Next 2Y-29.71%
EPS Next 3Y23.42%
EPS Next 5Y17.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%693.85%
Revenue Next Year79.08%
Revenue Next 2Y-46.55%
Revenue Next 3Y-56.47%
Revenue Next 5Y-43.89%
EBIT growth 1Y31.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y76.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.64%
OCF growth 3YN/A
OCF growth 5YN/A

XILIO THERAPEUTICS INC / XLO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of XILIO THERAPEUTICS INC (XLO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XLO.


Can you provide the valuation status for XILIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to XILIO THERAPEUTICS INC (XLO). This can be considered as Overvalued.


What is the profitability of XLO stock?

XILIO THERAPEUTICS INC (XLO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for XILIO THERAPEUTICS INC?

The Earnings per Share (EPS) of XILIO THERAPEUTICS INC (XLO) is expected to grow by 36.91% in the next year.